BioVergence
Core tokenization company
Standalone pipeline projects
Partners
We are building the BioV ecosystem across infrastructure, science, capital, and community
BioVergence is assembling the partners needed to help scientific assets move from signal to structure to market — across legal, tokenization, AI, manufacturing, diagnostics, and distribution.
Partners
We are seeking partners for the road ahead
We are seeking partners for the road ahead
We are seeking partners for the road ahead
Partner categories
Infrastructure Partners
Blockchain infrastructure
Tokenization platforms
Digital-asset custody and servicing
Digital-asset market infrastructure
Innovation Partners
AI partners
CDMOs
CROs
Diagnostics and platform development partners
Manufacturing Partners
Peptides
Diagnostics
Biosimilars
Adjacent product and protocol programs
Capital Partners
Family offices
Funds
Strategic investors
Sovereign and public-capital partners
Community & Distribution Partners
Health communities
Scientific networks
Creators and KOLs
Clinical and operator channels
Regulatory & Legal Partners
Swiss structuring
Cross-border compliance
Issuance counsel
Data and consent governance
Why partner with BioVergence
1
Patented IP and finance infrastructure
2
Active biopharma and science-asset relationships
3
Swiss legal and structuring foundation
4
Experienced industry, AI, and capital-markets leadership
5
Selective in-house and partner-led research / product programs
6
A growing community intelligence layer that improves sourcing, validation, and commercialization
Marketplace
BioVergence, its portfolio, and its new marketplace
BioVergence, its portfolio, and its new marketplace
BioVergence, its portfolio, and its new marketplace
There is a large and growing market for scientific-asset tokenization, and an opportunity to invest in BioVergence, its pipeline assets, and its token marketplace.
Core tokenization companyStandalone pipeline projectsRoyaltiesMilestonesRevenue participationFull-program tokensBiosimilarsMoonshotsStructured creditPortfolio vehiclesSovereign co-investmentCore tokenization companyStandalone pipeline projectsRoyaltiesMilestonesRevenue participationFull-program tokensBiosimilarsMoonshotsStructured creditPortfolio vehiclesSovereign co-investment
Yield Strategies
Royalties
Milestones
Revenue participation
Growth Strategies
Full-program tokens
Biosimilars
Moonshots
Institutional Strategies
Structured credit
Portfolio vehicles
Sovereign co-investment
Current yield and growth strategies
Yield strategies
Royalties
Milestones
Revenue participation
Growth strategies
Full-program vehicles
Biosimilars
Moonshots
Institutional strategies
Structured credit
Portfolio vehicles
Sovereign co-investment
BioVergence
Core tokenization platform
Selective standalone pipeline and product programs
Scientific assets and revenue streams
are becoming discoverablediscoverable
Tokenization turns IP, royalties, milestones, and program rights into instruments that can be owned, tracked, and transferred. That opens scientific value to a broader base of qualified investors, with clearer terms and a path to liquidity that bespoke private deals rarely reach.
FAQ
Frequently asked questions
Frequently asked questions
Frequently asked questions
What is your tokenization process?
Where do the scientific assets come from?
Who is BioVergence for?
How do I get started?
Partners
We are building the BioV ecosystem across infrastructure, science, capital, and community
BioVergence is assembling the partners needed to help scientific assets move from signal to structure to market — across legal, tokenization, AI, manufacturing, diagnostics, and distribution.
Partners
We are seeking partners for the road ahead
We are seeking partners for the road ahead
We are seeking partners for the road ahead
Partner categories
Infrastructure Partners
Blockchain infrastructure
Tokenization platforms
Digital-asset custody and servicing
Digital-asset market infrastructure
Innovation Partners
AI partners
CDMOs
CROs
Diagnostics and platform development partners
Manufacturing Partners
Peptides
Diagnostics
Biosimilars
Adjacent product and protocol programs
Capital Partners
Family offices
Funds
Strategic investors
Sovereign and public-capital partners
Community & Distribution Partners
Health communities
Scientific networks
Creators and KOLs
Clinical and operator channels
Regulatory & Legal Partners
Swiss structuring
Cross-border compliance
Issuance counsel
Data and consent governance
Why partner with BioVergence
1
Patented IP and finance infrastructure
2
Active biopharma and science-asset relationships
3
Swiss legal and structuring foundation
4
Experienced industry, AI, and capital-markets leadership
5
Selective in-house and partner-led research / product programs
6
A growing community intelligence layer that improves sourcing, validation, and commercialization
Marketplace
BioVergence, its portfolio, and its new marketplace
BioVergence, its portfolio, and its new marketplace
BioVergence, its portfolio, and its new marketplace
There is a large and growing market for scientific-asset tokenization, and an opportunity to invest in BioVergence, its pipeline assets, and its token marketplace.
Core tokenization companyStandalone pipeline projectsRoyaltiesMilestonesRevenue participationFull-program tokensBiosimilarsMoonshotsStructured creditPortfolio vehiclesSovereign co-investmentCore tokenization companyStandalone pipeline projectsRoyaltiesMilestonesRevenue participationFull-program tokensBiosimilarsMoonshotsStructured creditPortfolio vehiclesSovereign co-investment
BioVergence
Core tokenization company
Standalone pipeline projects
Yield Strategies
Royalties
Milestones
Revenue participation
Growth Strategies
Full-program tokens
Biosimilars
Moonshots
Institutional Strategies
Structured credit
Portfolio vehicles
Sovereign co-investment
Current yield and growth strategies
Yield strategies
Royalties
Milestones
Revenue participation
Growth strategies
Full-program vehicles
Biosimilars
Moonshots
Institutional strategies
Structured credit
Portfolio vehicles
Sovereign co-investment
BioVergence
Core tokenization platform
Selective standalone pipeline and product programs
Scientific assets and revenue streams
are becoming discoverablediscoverable
Tokenization turns IP, royalties, milestones, and program rights into instruments that can be owned, tracked, and transferred. That opens scientific value to a broader base of qualified investors, with clearer terms and a path to liquidity that bespoke private deals rarely reach.
FAQ